Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497340 | 0.88 | PDE2A (0.51) | PDE2AKAT2BHSD11B1EPHX2 | |
| SCHEMBL2824766 | 0.86 | POLB (0.41) | PDE2AKAT2BKDR | |
| SCHEMBL496563 | 0.86 | PDE2A (0.46) | PDE2AKAT2BAHR | |
| SCHEMBL496632 | 0.85 | MAPT (0.50) | PDE2AAHR | |
| SCHEMBL496929 | 0.84 | ABCG2 (0.44) | PDE2A | |
| SCHEMBL496562 | 0.84 | PDE2A (0.48) | PDE2AKAT2BAHR | |
| SCHEMBL2825175 | 0.84 | PDE2A (0.61) | PDE2AKAT2BAHR | |
| SCHEMBL496525 | 0.82 | CA9 (0.41) | PDE2AKAT2BHSD11B1 | |
| SCHEMBL496542 | 0.81 | PDE2A (0.44) | PDE2AKAT2BAHR | |
| SCHEMBL496760 | 0.81 | RXFP1 (0.46) | PDE2AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836207-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | disclosed |
| US-8106047-B2 | (4-Methoxyphenyl)-[3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine; phosphodiesterase inhibitors; septic shock or vascular edema; neoangiogenesis or inflammatory disease | NYCOMED GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-7851472-B2 | Triazolophthalazines | NYCOMED GMBH (DE) | 2010-12-14 | — | — | US | disclosed |
| US-20100286140-A1 | TRIAZOLOPHTHALAZINES | NYCOMED GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| EP-1791543-B1 | TRIAZOLOPHTHALAZINES | NYCOMED GMBH (DE) | 2010-06-16 | — | — | EP | disclosed |
| US-20090005372-A1 | Triazolophthalazines | ALTANA PHARMA AG (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20080312225-A1 | Triazolophthalazines | NYCOMED GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| EP-1836207-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | Nycomed GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1791543-A2 | TRIAZOLOPHTHALAZINES | Altana Pharma AG (DE) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006072615-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006024640-A2 | TRIAZOLOPHTHALAZINES | ALTANA PHARMA AG (DE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286140-A1 | TRIAZOLOPHTHALAZINES | PDE2A, PDE12, PDE3A | PDE2A 1/4885KAT2B 1046/4885PTGS1 134/4885 |
| US-20090005372-A1 | Triazolophthalazines | PDE2A, PDE12, PDE3A | PDE2A 1/4885KAT2B 1046/4885PTGS1 134/4885 |
| US-20080312225-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | PDE2A 1/4885KAT2B 1316/4885PTGS1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.